Date: 2011-08-01
Type of information: Licensing agreement
Compound: HuCAL GOLD technology
Company: Merck&Co (USA) Morphosys (Germany)
Therapeutic area:
Type agreement: licensing
Action mechanism:
Disease:
Details: AbD Serotec, MorphoSys’s research and diagnostic antibody unit, has amended its existing license agreement with Merck & Co., Inc. to include the use of MorphoSys's HuCAL GOLD technology in the field of vaccines. Under the terms of the agreement, Merck is granted access to HuCAL GOLD for research purposes, with the option to upgrade to MorphoSys's latest proprietary antibody library HuCAL PLATINUM.
Financial terms: AbD Serotec will receive annual user fees from Merck for access to the HuCAL technology and license fees for clinical monitoring reagents. Further financial details were not disclosed.
Latest news:
